Overview

The Use of Tulsi Extract for The Management of Oral Mucositis in Head & Neck Cancer Patients Undergoing Radiotherapy

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:
0

Participant gender:
All

Summary

After signing the informed consent, the participant will be allocated to either intervention or control group, then each participant will use either 0.15% benzydamine (Comparator) or 4% tulsi (Intervention) four times a day and also once half an hour before each radiotherapy session.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cairo University

Treatments:

Benzydamine

Criteria

Inclusion Criteria:

- Patients having clinical signs of radiotherapy-induced OM (WHO oral mucositis grading
scale: Grade II, III, and IV)

- Patient should be able to read and/or understand and sign the consent form.

Exclusion Criteria:

1. Patients with HIV infections or hyperthyroidism.

2. Karnofsky performance status (KPS) less than 60%

3. Patients having an allergy to tulsi or benzydamine HCL

4. Patients who are pregnant and/or nursing.